MedTrace Logo

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

NCT05193019 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 717

Last updated 2026-02-10

No results posted yet for this study

Summary

This registry will provide exploratory and descriptive information regarding contemporary practice patterns of parenteral antiplatelet therapy in the PCI (Percutaneous Coronary Intervention) setting and will investigate as well the short-term effectiveness and safety of the currently available parenteral antiplatelet agents in a cohort of "real-world" patients undergoing PCI in Spain.

Conditions

  • Ischemic Heart Disease
  • Acute Coronary Syndrome

Interventions

OTHER

Parenteral antiplatelet agents

Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice

Sponsors & Collaborators

  • Fundación EPIC

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2026-05-01
Completion
2026-06-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05193019 on ClinicalTrials.gov